Liquid biopsy
CTCs vs ctDNA: different analytes, different questions
What intact viable cells can support, what ctDNA does exceptionally well, and why a complementary research strategy is more defensible than a replacement claim.
Read article →VitraCell Insights
The evidence behind state-to-fate oncology research.
Source-linked analysis of longitudinal cell response, functional oncology, viable CTCs and the practical conditions in which an identity-preserved, low-input assay can add value to translational research.
Research and industry analysis for preclinical and translational use.
Drug response
Why same-cell history may matter in treatment resistance
What Rewind, fate-seq, ReSisTrace, live-cell approaches and DTP biology tell us—and what they do not prove for VitraCell.
Read article →Functional oncology
Where low-input assays could create real value
Why “rare” is not a business model, when expansion solves the problem, and where original-state preservation could matter economically.
Read article →Research framework
Delta State Response: computational feasibility and evidence boundary
How VitraCell has formalized the hypothesis, what synthetic modeling can establish, and what only a biological experiment can answer.
Read research note →Have a live problem?
Bring the decision, model and constraint.
If your team is studying heterogeneous treatment response, persistence or scarce viable material, VitraCell is interested in defining a bounded, falsifiable research study.
See the partner study model